...
首页> 外文期刊>Antiviral Research >Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens
【24h】

Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens

机译:诺如病毒药物候选物可抑制病毒衣壳与人组织血型组抗原的结合

获取原文
获取原文并翻译 | 示例

摘要

Human noroviruses are the leading causative agents of epidemic and sporadic viral gastroenteritis and childhood diarrhoea worldwide. Human histo-blood group antigens (HBGA) serve as receptors for norovirus capsid protein attachment and play a critical role in infection. This makes HBGA-norovirus binding a promising target for drug development. Recently solved crystal structures of norovirus bound to HBGA have provided a structural basis for identification of potential anti-norovirus drugs and subsequently performed in silico and in vitro drug screens have identified compounds that block norovirus binding and may thereby serve as structural templates for design of therapeutic norovirus inhibitors. This review explores norovirus therapeutic options based on the strategy of blocking norovirus-HBGA binding. (C) 2016 Elsevier B.V. All rights reserved.
机译:人类诺如病毒是世界范围内流行和偶发性病毒性肠胃炎和儿童腹泻的主要病原体。人类组织血型组抗原(HBGA)作为诺如病毒衣壳蛋白附着的受体,在感染中起关键作用。这使得HBGA-诺如病毒结合成为药物开发的有希望的目标。最近解决的与HBGA结合的诺如病毒的晶体结构为鉴定潜在的抗诺如病毒药物提供了结构基础,随后在计算机和体外药物筛选中鉴定出了可阻断诺如病毒结合的化合物,从而可作为治疗性模板设计的结构模板诺如病毒抑制剂。这篇综述基于阻断诺如病毒-HBGA结合的策略探讨了诺如病毒的治疗选择。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号